Anacetrapib {DEFINE Trial} – promising alternative to raise HDL chol and reduce LDL cholesterol

The recently released results of the DEFINE trial showed that patients taking anacetrapib, from a new class of medication (CETP inhibitors) reduced their LDL cholesterol (bad cholesterol) by approximately 40%, and raised their HDL cholesterol (good) by 140%. This trial is very promising, especially for patients who have primarily low HDL cholesterol, or those who are intolerant of the popular class of drugs called statins, like simvastatin, pravastatin, atorvastatin, or rosuvastatin. Please read further comments from the Heart.org website regarding this trial result.

Continue reading